Celsion Corporation Reports First Quarter 2014 Financial Results And Provides Business Update
Published: May 08, 2014
LAWRENCEVILLE, N.J., May 8, 2014 /PRNewswire/ -- Celsion Corporation /quotes/zigman/24125762/delayed/quotes/nls/clsn CLSN -4.20% , an oncology drug development company, today announced financial results for the first quarter ended March 31, 2014 and provided an update on its development program for ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III program for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
Help employers find you! Check out all the jobs and post your resume.